PALO ALTO, Calif., July 8, 2021 /PRNewswire/ -- BridgeBio Pharma,
Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver meaningful medicines
for patients with genetic diseases and cancers with clear genetic
drivers, today announced three new academic collaborations with
MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into
potential therapies for patients with genetic diseases and
genetically driven cancers.
"The chance to partner with exceptional researchers at the
Medical University of South Carolina,
Stanford University and University of Pittsburgh is a privilege, and we
believe will help us advance our mission to discover, create, test
and deliver life-changing medicines for patients in need as rapidly
as possible," said BridgeBio founder and CEO Neil Kumar, Ph.D.
To date, BridgeBio has worked with 23 leading institutions
throughout the country that are focused on providing treatment
options to patients as quickly and safely as possible. For a list
of some of the institutions BridgeBio is partnered with, please
visit Our Partners page.
MUSC Foundation for Research Development
MUSC
Foundation for Research Development provides technology transfer
services to Medical University of South
Carolina (MUSC), which is a patient-centric research
institution with several hospitals in South Carolina and is considered the state's
top healthcare provider. MUSC's innovative and high-quality
research will allow for early identification of research programs
with a strong potential to be beneficial for patients. Through this
partnership, BridgeBio may sponsor research programs and support
the development of identified programs toward potential clinical
investigation through its licensing and affiliate development
model.
"Like BridgeBio, we have a patients first mentality, so
partnering together on early research will be an excellent
opportunity to advance our innovation in the hope of generating new
therapies for patients," said Scott
Davis, Ph.D., senior director of innovation support and
commercialization of MUSC Foundation for Research Development.
Stanford University
This
formal collaboration between BridgeBio and Stanford is focused on unlocking new discoveries
and working to provide valuable treatment options to patients with
unmet needs. BridgeBio will work with Stanford researchers to identify new potential
therapies with the possibility of BridgeBio providing support for
these programs and potentially advancing them into clinical trials
and commercializing new medicines.
The University of Pittsburgh
(Pitt)
Pitt is one of the leading research institutions in
the United States with broad
strengths spanning basic research to clinical
translation. BridgeBio intends to collaborate with
Pitt to identify and support the
development of potential novel therapies for patients
with genetic diseases and cancers with clear genetic
drivers.
"We are very excited to grow our partnership with BridgeBio,"
said Rob A. Rutenbar, Ph.D., senior
vice chancellor for research at Pitt.
"Bringing together Pitt's leading
medical research enterprise with the drug development expertise of
BridgeBio serves our common goal of developing life-saving
therapies for those patients most in need."
About BridgeBio Pharma, Inc.
BridgeBio Pharma
(BridgeBio) is a biopharmaceutical company founded to discover,
create, test and deliver transformative medicines to treat patients
who suffer from genetic diseases and cancers with clear genetic
drivers. BridgeBio's pipeline of over 30 development programs
ranges from early science to advanced clinical trials and its
commercial organization is focused on delivering the company's
first two approved therapies. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information
visit bridgebio.com.
BridgeBio Pharma, Inc. Forward-Looking Statements
This
press release contains forward-looking statements. Statements we
make in this press release may include statements that are not
historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
(the "Securities Act"), and Section 21E of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), which are usually
identified by the use of words such as "anticipates," "believes,"
"estimates," "expects," "intends," "may," "plans," "projects,"
"seeks," "should," "will," and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act and are making this statement for
purposes of complying with those safe harbor provisions.
These forward-looking statements, including statements relating to
expectations, plans, and prospects regarding our partnering with
MUSC Foundation for Research Development on early research as an
opportunity to advance innovation in the hope of generating new
therapies for patients, the success of formal collaboration with
Stanford to unlock new discoveries and
provide valuable treatment options to patients with unmet needs,
the success of our collaboration with Pitt in identifying and supporting the development
of potential novel therapies for patients with genetic
diseases and cancers with clear genetic drivers, the success
of current and future relationships with third-party collaborators
and academic partners, and the potential ability of our product
candidates to treat genetically driven diseases and cancers with
clear genetic drivers, reflect our current views about our plans,
intentions, expectations, strategies and prospects, and are based
on the information currently available to us and on assumptions we
have made and are not forecasts, promises nor guarantees. Although
we believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by these forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially
from those described in the forward-looking statements and will be
affected by a number of risks, uncertainties and assumptions,
including, but not limited to, the success of our product
candidates to treat genetically driven diseases and cancers with
clear genetic drivers, the success of our academic collaborations
with each of MUSC Foundation for Research Development, Stanford University and Pitt, as well as those risks set forth in the Risk
Factors section of BridgeBio Pharma's most recent Annual Report on
Form 10-K and BridgeBio Pharma's other SEC filings. Moreover, we
operate in a very competitive and rapidly changing environment in
which new risks emerge from time to time. Except as required by
applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
BridgeBio Contact:
Grace
Rauh
BridgeBio Pharma, Inc.
Grace.rauh@bridgebio.com
(917) 232-5478
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bridgebio-pharma-announces-collaborations-with-three-academic-research-institutions-301327529.html
SOURCE BridgeBio